Epibiotech Co., Ltd. (CEO Seong Jong-hyuk) announced that it will participate in ‘BIO KOREA 5’ held at COEX, Seoul for three days from May 10 (Wed) to 12 (Fri).
Epibiotech is a bio venture that has been researching and developing hair loss treatments since its establishment in 2015. It has its own hair growth efficacy evaluation system and is developing new drug pipelines of various modalities that can treat hair loss. We are developing ‘first-in-class’ candidates, and are discovering new hair loss treatment targets such as CXCL12 neutralizing antibody and RIPK1 inhibitor in addition to dermal papilla cells, which are cell therapy products. Recognized as an innovative research and development research institute, it was designated as an excellent corporate research institute by the Ministry of Science and ICT in 2022, and its own GMP facility is designated as ‘advanced regenerative medicine and safety and support for advanced biopharmaceuticals’ for the development and handling of advanced biopharmaceuticals and cell/gene therapeutics. It has completed the acquisition of licenses for cell processing facilities, management of human cells, and advanced biopharmaceutical manufacturing, as stipulated by the Act.
In this exhibition, it introduces a hair growth efficacy evaluation platform specialized in the development of new drugs for hair loss, and the hair growth efficacy CRO service and CDMO service based on it.
Epibiotech is actively conducting a hair growth efficacy test (CRO) service business using the know-how of professional researchers who have studied hair loss for 10 years. We have published more than 30 SCI papers related to hair loss and have research know-how on various cells constituting hair follicles. Animal models for various hair loss diseases such as male pattern baldness, female pattern baldness, and alopecia areata have already been established, and tissue samples related to various hair loss diseases have been established. Its strength is that it can meet the needs of customers in a short time. Since 2021, it has conducted more than 20 commissioned researches and has experience evaluating the effectiveness of various materials.
Regarding this, an official from Epibiotech said, “The advantage of our CRO business is that it can quickly and accurately test drug efficacy in various hair loss model systems, and can perform everything from in vitro tests to ex vivo and mass animal tests. “The CDMO service of the cell therapy product production center, which is an in-house GMP facility, is a systematic GMP consulting of the entire process from consignment (development) production of advanced biopharmaceuticals and management of raw materials to finished drugs, and We can provide customized services according to your needs.”
As for the technology we have, we have established a GMP establishment and production process with patented technology related to dermal papilla cell isolation and culture, and we have secured technology related to hair follicle root sheath cell isolation and mass culture. It also has the know-how to secure a separate culture method for adipose stem cells and develop hair growth-related cell therapy products.
The hair loss treatment pipeline EPI-001 (dermal papilla cell treatment) under research and development is being supplemented after submitting the IND (clinical trial plan) for phase 2022 clinical trial in December 12, and phase 1 clinical trial is scheduled within the year. EPI-1 (small molecule therapy) completed non-clinical trials, EPI-002 (antibody therapy) was selected as a ‘new drug base expansion research project’ in the national new drug development project in 005, and EPI-2022 (allogeneic dermal papilla cell therapy) was selected by the government in 008 It has been selected for the regenerative medical technology development project and is currently performing the task. The pipeline is a domestic and overseas L/O plan after clinical trials.
An official said, “As the causes and symptoms of hair loss diversify and the market expands, the needs of our clients and clients also diversify. With our long hair loss research experience, it is possible to quickly evaluate candidate substances, so we expanded our CRO service while conducting commissioned research,” he said. -001) We plan to make additional funding for non-clinical trials.”
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th this year, is hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. Since 2006, BIO KOREA, which has been striving to promote the global status and continuous growth of the Korean health industry, has been strengthening its position as Korea’s representative bio-health international convention with world-renowned scholars and business experts participating every year. BIO KOREA 2023, together with domestic and foreign companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as companies and institutions of interest such as consulting, academia, and related organizations, offers various programs such as conferences, business partnering, exhibitions, and invest fairs. It goes on.